Disclosure Of Interests In Other Entities [Text Block]
| Concept |
2024-01-01 to 2024-12-31 |
2024-01-01 to 2024-12-31 |
2024-01-01 to 2024-12-31 |
As at 2024-12-31 |
2024-01-01 to 2024-12-31 |
2024-01-01 to 2024-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
As at 2023-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disclosure of interests in other entities [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of interests in subsidiaries [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of subsidiaries [text block] |
und ihre 100%igen Tochtergesellschaften Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, Biofrontera Development GmbH, und Biofrontera Neuroscience GmbH,
|
— | — | — | — | — | — | — | — | — | — | — |
| Disclosure of subsidiaries [abstract] | ||||||||||||
| Disclosure of subsidiaries [line items] | ||||||||||||
| Current assets | — | — | — |
16,255
EUR
|
— | — | — | — | — |
17,720
EUR
|
— | — |
| Non-current assets | — | — | — |
13,399
EUR
|
— | — | — | — | — |
13,012
EUR
|
— | — |
| Current liabilities | — | — | — |
10,469
EUR
|
— | — | — | — | — |
10,073
EUR
|
— | — |
| Non-current liabilities | — | — | — |
329,000
EUR
|
— | — | — | — | — |
678,000
EUR
|
— | — |
| Revenue |
21,666
EUR
|
— | — | — | — | — | — | — |
32,249
EUR
|
— | — | — |
| Profit (loss) |
4,350
EUR
|
0
EUR
|
0
EUR
|
— |
0
EUR
|
4,350
EUR
|
— |
0
EUR
|
369,000
EUR
|
— |
0
EUR
|
369,000
EUR
|
| Comprehensive income |
4,329
EUR
|
0
EUR
|
0
EUR
|
— |
21,000
EUR
|
4,350
EUR
|
0
EUR
|
1,000
EUR
|
368,000
EUR
|
— |
0
EUR
|
369,000
EUR
|
| Disclosure of interests in associates [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of associates [text block] |
Die Finanzanlagen beinhalten im Vorjahr den Beteiligungsbuchwert der Biofrontera Inc. in Höhe von 1.718 TEUR, die nach der At-Equity-Methode in den Konzernabschluss einbezogen und bewertet wurden. Aufgrund des Rückgangs der Anteile durch weitere Kapitalmaßnahmen des assoziierten Unternehmens und die damit verbundene Verwässerung der Anteile werden diese per 04. Januar 2024 nicht mehr als assoziiertes Unternehmen ausgewiesen. Aus dem Abgang des at-Equity Buchwertes hat sich ein Verlust in Höhe von 1.148 TEUR ergeben, welcher im Finanzergebnis ausgewiesen wurde.
|
— | — | — | — | — | — | — | — | — | — | — |
| Disclosure of associates [abstract] | ||||||||||||
| Disclosure of associates [line items] | ||||||||||||
| Other comprehensive income |
21,000
EUR
|
0
EUR
|
0
EUR
|
— |
21,000
EUR
|
0
EUR
|
0
EUR
|
1,000
EUR
|
1,000
EUR
|
— |
0
EUR
|
0
EUR
|
| Investments accounted for using equity method | — | — | — |
0
EUR
|
— | — | — | — | — |
1,718
EUR
|
— | — |
| Disclosure of interests in joint arrangements [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of joint ventures [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of joint ventures [abstract] | ||||||||||||
| Disclosure of joint ventures [line items] | ||||||||||||
| Cash and cash equivalents | — | — | — |
3,124
EUR
|
— | — | — | — | — |
3,080
EUR
|
— | — |
| Other current financial liabilities | — | — | — |
48,000
EUR
|
— | — | — | — | — |
71,000
EUR
|
— | — |
| Interest income |
64,000
EUR
|
— | — | — | — | — | — | — |
21,000
EUR
|
— | — | — |
| Interest expense |
11,000
EUR
|
— | — | — | — | — | — | — |
15,000
EUR
|
— | — | — |
| Tax expense (income) |
2,369
EUR
|
— | — | — | — | — | — | — |
1,758
EUR
|
— | — | — |
| Disclosure of investment entities [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of effect of change of investment entity status on financial statements [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Gain (loss) on cessation of consolidation of subsidiaries due to change of investment entity status | — | — | — | — | — | — |
0
EUR
|
0
EUR
|
0
EUR
|
— |
0
EUR
|
0
EUR
|